MorphoSys Targets 2020 Tafasitamab Launch Following Good DLBCL Data
Morphosys says good L-MIND Phase II data back its plan to submit a US BLA to the US Food and Drug Administration by year-end, for a potential mid-2020 approval of tafasitamab.
Morphosys says good L-MIND Phase II data back its plan to submit a US BLA to the US Food and Drug Administration by year-end, for a potential mid-2020 approval of tafasitamab.